Abstract:A strategy is presented to augment the protein degradation capability of proteolysis targeting chimeras (PROTACs) by modulating external nutrient supply and employing nanocarrier‐based targeted delivery. The results demonstrate that a reduction in nutrient supply can enhance protein metabolism and significantly improve the therapeutic efficacy of PROTACs when combined with nanocarriers. The ubiquitin‐proteasome system (UPS) is responsible for degrading over 70–80% of cellular proteins. Consequently, proteolysis‐targeting chimeras (PROTACs) are developed to induce the ubiquitination and subsequent degradation of proteins of interest (POIs) by the UPS. To amplify the therapeutic efficacy of PROTACs, energy metabolism regulation is first harnessed to boost UPS function in tumor cells. Proteomic and ubiquitinome analyzes reveal that total ubiquitinated proteins and proteasome activity are significantly increased in 143B and MDA‐MB‐231 tumor cells following fasting‐mimicking diet (FMD) treatment. As a result, the degradation efficiency of PROTACs targeting focal adhesion kinase (FAK‐P) or bromodomain‐containing protein 4 (BRD4‐P) is significantly enhanced in FMD‐treated 143B and MDA‐MB‐231 tumor cells. Then, silica‐coated iron oxide nanoparticles are developed modified with tumor cell membranes for targeted delivery of PROTACs. Magnetic resonance imaging (MRI) and fluorescence imaging confirm that nanocarriers significantly improve the delivery efficiency of PROTACs in FMD‐treated 143B or MDA‐MB‐231 tumors. In vivo studies demonstrate that the antitumor efficacy of FAK‐P and BRD4‐P is greatly augmented when combined with targeted delivery and FMD treatment. Overall, this study presents a strategy to enhance the efficacy of PROTACs in cancer therapy.

Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins

Cancer Selective Target Degradation By Folate-Caged Protacs

Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo.

Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Selective Protein of Interest Degradation Through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

Transferrin receptor targeting chimeras for membrane protein degradation

Glucose Transporter-Targeting Chimeras Enabling Tumor-Selective Degradation of Secreted and Membrane Proteins

Progress of Targeted Therapy on the Cancer Mediated Mate Receptor

Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy

Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Development of natural product-based targeted protein degraders as anticancer agents

Augmenting Protein Degradation Capacity of PROTAC through Energy Metabolism Regulation and Targeted Drug Delivery